<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003198" GROUP_ID="DEPRESSN" ID="628499082614545060" MERGED_FROM="" MODIFIED="2008-11-06 03:58:08 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-06 02:55:14 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="055" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2008-11-06 03:58:08 +0100" MODIFIED_BY="Rachel Churchill">
<TITLE>Tryptophan and 5-Hydroxytryptophan for depression</TITLE>
<CONTACT MODIFIED="2008-11-06 03:58:08 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="14744" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kelly</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Shaw</LAST_NAME><POSITION>Honorary Associate</POSITION><EMAIL_1>kelly.shaw@dhhs.tas.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Menzies Research Institute</DEPARTMENT><ORGANISATION>Public Health Unit</ORGANISATION><ADDRESS_1>2/152 Macquarie Street</ADDRESS_1><CITY>Hobart </CITY><ZIP>7000</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 6222 7678</PHONE_1><FAX_1>+61 3 6222 7407</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-06 03:58:08 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="14744" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kelly</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Shaw</LAST_NAME><POSITION>Honorary Associate</POSITION><EMAIL_1>kelly.shaw@dhhs.tas.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Menzies Research Institute</DEPARTMENT><ORGANISATION>Public Health Unit</ORGANISATION><ADDRESS_1>2/152 Macquarie Street</ADDRESS_1><CITY>Hobart </CITY><ZIP>7000</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 6222 7678</PHONE_1><FAX_1>+61 3 6222 7407</FAX_1></ADDRESS></PERSON><PERSON ID="13239" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jane</FIRST_NAME><LAST_NAME>Turner</LAST_NAME><POSITION>Senior Lecturer</POSITION><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Queensland</ORGANISATION><ADDRESS_1>Department of Psychiatry</ADDRESS_1><ADDRESS_2>Royal Brisbane Hospital</ADDRESS_2><CITY>Herston</CITY><ZIP>4006</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="12249" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Chris</FIRST_NAME><LAST_NAME>Del Mar</LAST_NAME><SUFFIX>MA MB BChir MD FRACGP FAFPHM</SUFFIX><POSITION>Dean</POSITION><EMAIL_1>cdelmar@bond.edu.au</EMAIL_1><URL>http://ari.cochrane.org/en/about.html</URL><MOBILE_PHONE>+61 403 220080</MOBILE_PHONE><ADDRESS><DEPARTMENT>Faculty of Health Sciences and Medicine</DEPARTMENT><ORGANISATION>Bond University</ORGANISATION><ADDRESS_1>University Pde</ADDRESS_1><ADDRESS_2>Robina</ADDRESS_2><CITY>Gold Coast</CITY><ZIP>4229</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 5595 5499</PHONE_1><FAX_1>+61 7 5595 4122</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-06 03:58:08 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Minor update: 12/01/05&lt;/p&gt;&lt;p&gt;New studies sought but none found: 12/02/08&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 12/01/05&lt;/p&gt;&lt;p&gt;Feedback added: 24/05/05&lt;/p&gt;" NOTES_MODIFIED="2008-11-06 02:51:09 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="12" MONTH="2" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="2" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2002"/>
</DATES>
<WHATS_NEW NOTES="&lt;p&gt;Search strategy repeated. Three new studies assessed for inclusion in the review (Levitan 2000, Russ 1990, Kline 1973). All excluded from the review. Reasons for exclusion are outlined in the table: &amp;quot;Characteristics of excluded studies&amp;quot;.&lt;br&gt;&lt;br&gt;12/2/2008 - An updating search was run but no new studies were identified&lt;/p&gt;">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="6" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="28" MONTH="11" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Royal Australian College of General Practitioners</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-06 02:55:14 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-06 02:52:30 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-06 02:52:30 +0000" MODIFIED_BY="[Empty name]">Tryptophan and 5-Hydroxytryptophan for depression</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-06 02:51:36 +0000" MODIFIED_BY="[Empty name]">
<P>5-HTP (Hydroxytryptophan) and tryptophan have been examined to see whether these treatments are effective, safe and acceptable in treating unipolar depression in adults. The researchers reported that the symptoms of depression decreased when 5-HTP and tryptophan were compared to a placebo (non-drug). However, side effects had occurred (dizziness, nausea and diarrhoea). They also reported that tryptophan has been associated with the development of a fatal condition. More evidence is needed to assess efficacy and safety, before any strong and meaningful conclusions can be made. Until then, the reviewers propose that the use of antidepressants which have no known life threatening side effects remain more attractive. The review sets out the required methodology for effectively studying these substances in proper controlled studies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-06 02:54:10 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>5 Hydroxytryptophan (5-HTP) and tryptophan are so-called natural alternatives to traditional antidepressants, used to treat unipolar depression and dysthymia.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-11-06 02:53:53 +0000" MODIFIED_BY="[Empty name]">
<P>To determine whether 5-HTP and tryptophan are more effective than placebo, and whether they are safe to use to treat depressive disorders in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-06 02:54:06 +0000" MODIFIED_BY="[Empty name]">
<P>CCDANCTR-Studies and CCDANCTR-References were searched on 12/2/2008). Reference lists, book chapters and conference proceedings were checked. Experts and trialists were contacted for unpublished studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Trials were included if they were randomized, included patients with unipolar depression or dysthymia, compared preparations of 5-HTP or tryptophan with placebo, and included clinical outcomes assessed by scales assessing depressive symptoms.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data was extracted independently by the three reviewers, onto data collection forms. Inclusion criteria were applied to all potential studies independently and a coefficient of agreement (Kappa) was calculated for them. Disagreement was resolved by reaching consensus. Trial quality was scored according to risk of bias. Analysis for 5-HTP and tryptophan were combined due to the small number of included trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>108 trials were located using the specified search strategy in 2001. An additional three trials were located when the search strategy was repeated in 2004. Of the total number of trials located in both searches, only two trials, involving a total of 64 patients, were of sufficient quality to meet inclusion criteria. The available evidence suggests these substances were better than placebo at alleviating depression (Peto Odds Ratio 4.10; 95% confidence interval 1.28-13.15; RD 0.36; NNT 2.78). However, the evidence was of insufficient quality to be conclusive.<BR/> </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-06 02:54:10 +0000" MODIFIED_BY="[Empty name]">
<P>A large number of studies appear to address the research questions, but few are of sufficient quality to be reliable. Available evidence does suggest these substances are better than placebo at alleviating depression. Further studies are needed to evaluate the efficacy and safety of 5-HTP and tryptophan before their widespread use can be recommended. The possible association between these substances and the potentially fatal Eosinophilia-Myalgia Syndrome has not been elucidated. Because alternative antidepressants exist which have been proven to be effective and safe the clinical usefulness of 5-HTP and tryptophan is limited at present.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-06 02:55:06 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Depression is the most commonly diagnosed psychiatric condition (<LINK REF="REF-Edgell-1972" TYPE="REFERENCE">Edgell 1972</LINK>). There are many theories regarding aetiology of depression. However, its precise aetiology is still largely unknown (<LINK REF="STD-Rousseau-1987" TYPE="STUDY">Rousseau 1987</LINK>). For many years cerebral serotonin deficiency has been recognised as a possible cause of depression. This hypothesis has been supported by demonstrating improvement in depression in patients receiving medications known to increase cerebral serotonin precursor levels (<LINK REF="REF-Pare-1959" TYPE="REFERENCE">Pare 1959</LINK>; <LINK REF="REF-Coppen-1963" TYPE="REFERENCE">Coppen 1963</LINK>), and by postmortem analysis of cerebral and CSF tissue demonstrating serotonin deficiency in affected individuals (<LINK REF="REF-Shaw-1967" TYPE="REFERENCE">Shaw 1967</LINK>; <LINK REF="REF-Bourne-1968" TYPE="REFERENCE">Bourne 1968</LINK>; <LINK REF="REF-Pare-1969" TYPE="REFERENCE">Pare 1969</LINK>). </P>
<P>Antidepressants remain the mainstay of therapy for patients with depression, with psychotherapy playing a very important adjunctive role (<LINK REF="REF-Edgell-1972" TYPE="REFERENCE">Edgell 1972</LINK>). There is an increasing trend towards the use of so-called natural alternatives to traditional antidepressants. These alternatives include substances such as St Johns Wort, Kava-Kava, tyrosine, tryptophan and 5-Hydroxy-L-tryptophan (5-HTP) (<LINK REF="REF-Jorm-1997" TYPE="REFERENCE">Jorm 1997</LINK>). Tryptophan and 5-HTP are the focus of this review.</P>
<P>5-HTP is synthesised from the amino acid tryptophan. The body absorbs tryptophan, converts it to 5-HTP then forms it into serotonin, both centrally and peripherally (<LINK REF="REF-Lader-1981" TYPE="REFERENCE">Lader 1981</LINK>). Both tryptophan and 5-HTP are able to penetrate the blood-brain barrier. A normal Western diet contains about 0.5g of tryptophan daily, of which only 2-3% is used in central serotonin production (<LINK REF="REF-Beckmann-1983" TYPE="REFERENCE">Beckmann 1983</LINK>). Tryptophan is transported across the blood-brain barrier by a carrier mechanism which also transports tyrosine, pheylalanine, leucine, isoleucine, and valine. </P>
<P>Increase in dietary tryptophan increases the amount transported across the blood-brain barrier. Increase in the other amino acids transported by the same carrier reduces the transport of tryptophan (<LINK REF="REF-Wurtman-1976" TYPE="REFERENCE">Wurtman 1976</LINK>; <LINK REF="REF-Wurtman-1981" TYPE="REFERENCE">Wurtman 1981</LINK>). </P>
<P>5-HTP penetrates the brain and is converted to serotonin within serotonergic neurons, and neurotransmitter within dopaminergic and noradrenergic neurons (<LINK REF="REF-Lader-1981" TYPE="REFERENCE">Lader 1981</LINK>). Therefore, depressed patients administered 5-HTP or tryptophan should experience improvement. However clinical trials in which patients have been administered tryptophan or 5-HTP have given conflicting results and reached differing conclusions. Some reviewers have found both substances to have an antidepressant effect (<LINK REF="REF-Gelenberg-1982" TYPE="REFERENCE">Gelenberg 1982</LINK>; <LINK REF="REF-Praag-1981" TYPE="REFERENCE">Praag 1981</LINK>). Other reviewers have found the evidence supporting use of tryptophan and 5-HTP for depression to be weak (<LINK REF="REF-Murphy-1978" TYPE="REFERENCE">Murphy 1978</LINK>; <LINK REF="REF-D_x0027_Elia-1978" TYPE="REFERENCE">D'Elia 1978</LINK>; <LINK REF="REF-Beckmann-1983" TYPE="REFERENCE">Beckmann 1983</LINK>).</P>
<P>5-HTP and tryptophan are both known to have side effects. Nausea and gastrointestinal distress are the most notable, making it very difficult to blind participants to treatment in randomized controlled trials. Of greater concern is the possible association of tryptophan with Eosinophilia-Myalgia Syndrome (EMS). This syndrome affected nearly 1 500 tryptophan users in 1989 and led to over 30 deaths. It is still uncertain whether the tryptophan, which contained an impurity identified by analytical chromatography, was the cause (<LINK REF="REF-Toyo_x0027_oka-1991" TYPE="REFERENCE">Toyo'oka 1991</LINK>). Tryptophan was subsequently withdrawn from the market in the USA (<LINK REF="REF-Blackburn-1997" TYPE="REFERENCE">Blackburn 1997</LINK>). The nature of the tryptophan-EMS association has not yet been fully elucidated. It is also possible it is a chance association only, it is due to excess tryptophan itself, or it is due to a combination of the impurity and excess tryptophan (<LINK REF="REF-Horowitz-1996" TYPE="REFERENCE">Horowitz 1996</LINK>). A similar impurity has recently been identified in 5-HTP. The significance of this is also unknown (<LINK REF="REF-Michelson-1994" TYPE="REFERENCE">Michelson 1994</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>1. To evaluate the efficacy and acceptability of 5-HTP in unipolar depression.<BR/>2. To evaluate the efficacy and acceptability of tryptophan in unipolar depression.</P>
<P>The following hypotheses were tested:<BR/>1. 5-HTP is more effective than placebo in the treatment of unipolar depression.<BR/>2. Tryptophan is more effective than placebo in the treatment of unipolar depression.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-06 02:54:50 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-06 02:54:46 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Studies compared 5-HTP or tryptophan to inert placebo. <BR/>Studies included a design which involved double blind randomized allocation to treatment groups. <BR/>Quasi-randomized trials were considered for inclusion and analysis separately.<BR/>Trials included some measurement of depression as an outcome variable.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Trials contained a comparison group receiving inert placebo.<BR/>Trials of adults with unipolar depression diagnosed according to any recognised criteria, irrespective of age, gender, race or nationality were eligible for inclusion. <BR/>Ambulatory settings and hospital settings were included. <BR/>Patients with a concurrent diagnosis of another psychiatric or medical disorder were included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Trials compared either 5-HTP or tryptophan to placebo.<BR/>Comparison groups were allocated to active treatment or inert placebo. <BR/>Placebos excluded any currently used antidepressant drug.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-06 02:54:46 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes of interest were:<BR/>1 - change in depression by the end of the trial as determined by symptom scale. Clinical improvement or exacerbation or no change was determined by symptom scale measurement.<BR/>2 - acceptability of the treatment as measured by drop-out during the trial and post randomisation exclusions, numbers reporting at least one side-effect during the trial, specific side-effects, and deaths.<BR/>3 - relapse of depression.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: Collaborative Review Group Strategy</P>
<P>
<B>1. Electronic Searching</B>
<BR/>The CCDAN registers were searched as follows</P>
<P>CCDANCTR-Studies (searched on 12/2/2008)<BR/>Diagnosis = Depress* or Dysthymi* or "Adjustment Disorder*" or "Mood Disorder*" or "Affective Disorder" or "Affective Symptoms")<BR/>and<BR/>Intervention = tryptophan or 5-htp or 5-hydroxtryptophan or Hydroxytryptophan<BR/>and<BR/>Intervention = Placebo</P>
<P>CCDANCTR-References (searched on 12/2/2008)<BR/>Keyword = Depress* or Dysthymi* or "Adjustment Disorder*" or "Mood Disorder*" or "Affective Disorder" or "Affective Symptoms")<BR/>and<BR/>Free-text = tryptophan or 5-htp or 5-hydroxtryptophan or Hydroxytryptophan<BR/>
<BR/>
<B>2. Hand Searching</B>
<BR/>The reference lists of included studies were scanned for published reports and citations of unpublished research.</P>
<P>Book chapters on treatment of depression were scanned for description of trials.</P>
<P>Conference abstracts were searched for references.</P>
<P>
<B>3. Personal Communication</B>
<BR/>Unpublished data was to be sought from relevant authors and experts in the field</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-06 02:54:50 +0000" MODIFIED_BY="[Empty name]">
<P>LOCATING AND SELECTING STUDIES<BR/>Three reviewers (KS, JT and CDM) carried out the inclusion criteria application.<BR/>The inclusion criteria were applied to all potential studies independently and a coefficient of agreement (Kappa) calculated.<BR/>Disagreement was resolved by reaching consensus.</P>
<P>CRITICAL APPRAISAL<BR/>The methodological quality of the included studies was independently evaluated by the three reviewers.<BR/>Details of method of randomisation, blinding, whether intention-to-treat analysis was done, and number of patients lost to follow up was recorded.<BR/>The trials were scored according to concealment of allocation (A=low risk, B=moderate risk, C=high risk) (Cochrane Handbook 1994).</P>
<P>COLLECTING DATA<BR/>The results of each trial were summarised on an intention-to-treat basis in 2x2 tables for each outcome, for tryptophan and 5-HTP separately. Only trials with a score of A and B were used.</P>
<P>ANALYSING AND PRESENTING RESULTS<BR/>
</P>
<P>The studies were grouped for meta-analysis according to the appraisal above. 5-HTP and tryptophan were analysed together due to the small number of trials which met inclusion criteria. Meta-analysis was performed (Review Manager 4.01) using various techniques. The Peto odds ratio, odds ratio, relative risk, risk difference were all calculated. When overall results were significant both the relative risk reduction (RRR) and number needed to treat (NNT) were calculated. Additionally, the number needed to harm (NNH) and the confidence interval around these measures were calculated.</P>
<P>Graphical presentations were assessed also.</P>
<P/>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-06 02:54:54 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-06 02:54:54 +0000" MODIFIED_BY="[Empty name]">
<P>See: Tables of characteristics of included and excluded studies</P>
<P>In 2001, a total of 108 clinical controlled or possibly trials that investigated 5-HTP and tryptophan in depression were located using the above search strategy. Forty-nine studies were excluded on the basis of the abstract as they were not limited to 5-HTP or tryptophan as a treatment for depression. Fifty-nine trials were quality scored using the original article as the abstract was not sufficiently detailed to draw conclusions about the study. Of these, 23 were excluded as they were not placebo controlled, four were excluded as they did not evaluate the efficacy of 5-HTP or tryptophan as a monotherapy, six were excluded as they did not pertain primarily to depression, two were excluded as they were double publications of the same trial, and 11 were excluded as they were not adequately randomized or double blind. The 11 remaining trials, including two non-English language trials, were evaluated. Three were subsequently excluded on the basis of methodologic weaknesses and inability to extract necessary parameters from the results. Six were excluded as they were crossover trials. The remaining two trials, including a total of 64 patients met inclusion criteria (<LINK REF="STD-Thomson-1982" TYPE="STUDY">Thomson 1982</LINK>, <LINK REF="STD-Van-Praag-1972" TYPE="STUDY">Van Praag 1972</LINK>).</P>
<P>The search strategy was repeated in 2004. An additional 27 abstracts were located. Twenty-four abstracts were excluded as they were not limited to 5-HTP or tryptophan as a treatment for depression. Three trials were quality scored using the original article. Of these, one was excluded as it did not evaluate the efficacy of 5-HTP or tryptophan as a monotherapy (<LINK REF="STD-Levitan-2000" TYPE="STUDY">Levitan 2000</LINK>), one was a case-control study (<LINK REF="STD-Russ-1990" TYPE="STUDY">Russ 1990</LINK>), and one did not have a placebo group for comparison (<LINK REF="STD-Kline-1973" TYPE="STUDY">Kline 1973</LINK>).</P>
<P>Participants had depression varying in severity from mild to severe. The duration of the studies was short - up to 10 weeks. One study assessed 5-HTP, the other, tryptophan. The Hamilton Depression Rating Scale was used as the primary measure of response to treatment. The Global Rating Scale, Venables scale, Zung scale and Visual Analogue Scale were also used.</P>
<P>Out of the total of 64 patients in the trials, seven patients on active treatment withdrew from the study prematurely, compared with 11 patients on inactive placebo.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>See: Table of characteristics of included studies</P>
<P>The description of concealment of allocation was rated as A in both studies (<LINK REF="STD-Thomson-1982" TYPE="STUDY">Thomson 1982</LINK>, <LINK REF="STD-Van-Praag-1972" TYPE="STUDY">Van Praag 1972</LINK>). </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>The small number of patients included overall increases the risk of publication bias and makes generalization about efficacy of 5-HTP and tryptophan difficult, however, the results indicated that 5-HTP and tryptophan were better than placebo at alleviating symptoms of depression (Peto odds ratio 4.10; 95% confidence interval 1.28 - 13.15). The risk difference was 0.36 and the number needed to treat 2.78. The number of patients on active treatment reporting side-effects was four. Dizziness, nausea and diarrhoea were the side-effects cited. The number needed to harm was not calculated due to small numbers. No deaths related to the use of 5-HTP or tryptophan were reported in the studies. There were no side-effects in the placebo groups.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-06 02:55:06 +0000" MODIFIED_BY="[Empty name]">
<P>A large number of studies are available which appear to address the research questions, however few are of sufficient quality to be reliable. Available evidence from randomized trials is insufficient to evaluate conclusively whether or not 5-HTP and/or tryptophan have any superior effect over placebo in the treatment of mild to severe unipolar depression. Available evidence does, however, suggest these substances are better than placebo at alleviating depression.There are insufficient data to evaluate the side-effect profile of each treatment, and their relative safety.</P>
<P>Randomized controlled trials that have evaluated clinical effects of 5-HTP and tryptophan treatment for depressive disorders are limited in their reliability by poor methodological quality (see table - Excluded Studies). Trials varied significantly regarding severity of depression, doses of 5-HTP and tryptophan studied, settings, and comparative interventions. In several trials comparing 5-HTP and tryptophan to other antidepressants, the 5-HTP and tryptophan were used instead of placebo because it was assumed that they were no better than placebo in managing depression, and because ethics committees in several instances felt it was unethical to use an 'inactive' placebo in depressed inpatients (<LINK REF="STD-Seppala-1978" TYPE="STUDY">Seppala 1978</LINK>; <LINK REF="STD-Linnoila-1980" TYPE="STUDY">Linnoila 1980</LINK>). A comparison of 5-HTP and tryptophan with other available antidepressants was not performed in this review.</P>
<P>Tolerability of 5-HTP and tryptophan was acceptable in the included studies. Few adverse effects were noted. Side-effects resulting in withdrawal were dizziness and epigastric pain. Diarrhoea was also reported but did not result in patient withdrawal. No patient in the placebo group withdrew due to side-effects. No deaths were reported. Published case reports, however, have questioned the link between tryptophan and the development of eosinophilia-myalgia syndrome, which has been fatal in an number of cases (<LINK REF="REF-Toyo_x0027_oka-1991" TYPE="REFERENCE">Toyo'oka 1991</LINK>). The link has, to date, remained unproven. The same impurity identified in tryptophan has also been found in 5-HTP (<LINK REF="REF-Horowitz-1996" TYPE="REFERENCE">Horowitz 1996</LINK>; <LINK REF="REF-Michelson-1994" TYPE="REFERENCE">Michelson 1994</LINK>). Systematic studies evaluating long-term side effects of 5-HTP and tryptophan do not exist.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Results of this meta-analysis are inconclusive due to the small number of sufficiently rigorous studies available on which to base conclusions. It is therefore difficult to recommend or discourage the use of 5-HTP and tryptophan in treatment of unipolar depression. More evidence is clearly needed to assess efficacy. Although the order of magnitude of effectiveness of 5-HTP and tryptophan was found in this study to be similar to Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs), the body of evidence evaluating the efficacy and safety of SSRIs and TCAs is more rigorous and comprehensive (<LINK REF="REF-Trindade-1997" TYPE="REFERENCE">Trindade 1997</LINK>). Also, the relative potency of SSRIs and TCAs is possibly much greater, even though order of effectiveness is comparable. In settings where depression is mild, and the use of traditional antidepressants is unacceptable to the patient, tryptophan and 5-HTP may be considered as treatment alternatives.</P>
<P>The possible link between tryptophan and 5-HTP and a potentially fatal side-effect makes their clinical use less appealing until this issue is resolved, particularly due to the availability of other antidepressants with proven efficacy and safety.</P>
<P>A further issue complicating use of 5-HTP and tryptophan is the type of preparation and dose. Trials evaluated used widely varying doses and dosage schedules. No consensus about appropriate dosage and frequency of administration exists to guide the clinician's prescribing.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P> Large, well designed, placebo-controlled, randomized controlled trials are needed to assess clinical utility of 5-HTP and tryptophan in the treatment of depression. Future studies should focus on the following issues:<BR/>- evaluation of efficacy in well-defined subgroups of patients with unipolar depression of varying severity<BR/>- evaluation of side-effects, particularly potentially life-threatening side-effects.<BR/>- comparisons of different dosage, frequency of administration, and preparations of 5-HTP and tryptophan</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Thanks to Anneliese Spinks (Research Officer, Department of Social and Preventive Medicine, University of Queensland) for assistance with computer software and data editing. Thanks to Li Chen (PhD student, Department of Psychiatry, University of Queensland) and Anabel Bardossy for their assistance with translating non-English language articles.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-06 02:55:14 +0000" MODIFIED_BY="[Empty name]">
<P>KELLY SHAW: Protocol development, literature search, assessment of trials and data extraction. Principal reviewer performing the analysis and interpretation of data, as well as the development of the final review.</P>
<P>JANE TURNER: Assessment of trials, data extraction and development of the final review.</P>
<P>CHRISTOPHER DEL MAR: Assessment of trials and data extraction, interpretation of the data and development of the final review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomson-1982" NAME="Thomson 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Thomson J, Rankin H, Ashcroft G, Yates C, McQueen J, Cummings S</AU>
<TI>The treatment of depression in general practice: A comparison of L-tryptophan, amitriptyline, and a combination of L-Tryptophan and Amitriptyline with placebo</TI>
<SO>Psychological Medicine</SO>
<YR>1982</YR>
<VL>12</VL>
<PG>741-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Praag-1972" NAME="Van Praag 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Praag HM, Korf J</AU>
<TI>5-Hydroxytryptophan as antidepressant: The predictive value of the probenecid test</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1972</YR>
<VL>8</VL>
<NO>4</NO>
<PG>34-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Praag J, Korf J, Dols L, Schut T</AU>
<TI>A pilot study of the predictive value of the probenecid test in application of 5-Hydroxytryptophan as antidepressant</TI>
<SO>Psychopharmacology</SO>
<YR>1972</YR>
<VL>25</VL>
<PG>14-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Alino-1976" NAME="Alino 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alino J, Gutierrez J, Iglesias M</AU>
<TI>5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depression. A double blind controlled study</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1976</YR>
<VL>11</VL>
<NO>1</NO>
<PG>8-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angst-1977" NAME="Angst 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Angst J, Woggon B, Schoepf J</AU>
<TI>The treatment of depression with L-5-Hydroxytryptophan versus imipramine. Results of two open and one double-blind study</TI>
<SO>Archiv fuer Psychiatrie und Nervenkrankheiten</SO>
<YR>1977</YR>
<VL>224</VL>
<NO>2</NO>
<PG>175-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asheychik-1989" NAME="Asheychik 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Asheychik R, Jackson T, Baker H, Ferraro R, Ashton T, Kilgore J</AU>
<TI>The efficacy of L-Tryptophan in the reduction of sleep disturbance and depressive state in alcoholic patients</TI>
<SO>Journal of Studies on Alcohol</SO>
<YR>1989</YR>
<VL>50</VL>
<NO>6</NO>
<PG>525-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayuso-1971-a" NAME="Ayuso 1971 a" YEAR="1971">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ayuso Gutierrez J, Lopez-Ibor Alino J</AU>
<TI>Tryptophan and an MAOI (Nialamide) in the treatment of depression</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1971</YR>
<VL>6</VL>
<NO>2</NO>
<PG>92-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barker-1987" NAME="Barker 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barker W, Scott J, Eccleston D</AU>
<TI>The Newcastle chronic depression study: Results of a treatment regime</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>3</NO>
<PG>261-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-1994" NAME="Barr 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS et al</AU>
<TI>Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>4</NO>
<PG>309-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brewerton-1992" NAME="Brewerton 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brewerton TD, Mueller EA, Lesem MD, Brandt HA, Quearry B, George DT et al.</AU>
<TI>Neuroendocrine responses to m-chlorphenylpiperazine and L-tryptophan in bulimia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>11</NO>
<PG>852-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carroll-1970" NAME="Carroll 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carroll B, Mowbray R, Davies B</AU>
<TI>Sequential comparison of L-tryptophan with ECT in severe depression</TI>
<SO>Lancet</SO>
<YR>1970</YR>
<VL>1</VL>
<NO>654</NO>
<PG>967-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1978" NAME="Chouinard 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Young S, Annable L, Sourkes T</AU>
<TI>Tryptophan dosage critical for its antidepressant effect</TI>
<SO>BMJ</SO>
<YR>1978</YR>
<VL>1</VL>
<PG>1422</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Young SN, Annable L, Sourkes TL</AU>
<TI>Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1979</YR>
<VL>59</VL>
<NO>4</NO>
<PG>395-414</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-1980" NAME="Cooper 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cooper A, Datta S</AU>
<TI>A placebo controlled evaluation of L-Tryptophan in depression in the elderly</TI>
<SO>Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie</SO>
<YR>1980</YR>
<VL>25</VL>
<NO>5</NO>
<PG>386-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coppen-1970" NAME="Coppen 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coppen A, Noguera R</AU>
<TI>L-tryptophan in depression</TI>
<SO>Lancet</SO>
<YR>1970</YR>
<VL>1</VL>
<NO>7656</NO>
<PG>1111</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coppen A, Whybrow B, Nogura R, Maggs R, Prange A Jr</AU>
<TI>The comparative antidepressant value of L-Tryptophan and Imipramine with and without attempted potentiation by lyothyronine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<PG>234-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whybrow PC, Coppen A, Prange AJ Jr, Noguera R, Bailey JE</AU>
<TI>Thyroid function and the response to liothyronine in depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<NO>3</NO>
<PG>242-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coppen-1976-c" NAME="Coppen 1976 c" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coppen A</AU>
<TI>Treatment of unipolar depression</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>1</VL>
<NO>7950</NO>
<PG>90-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Elia-1977-b" NAME="D'Elia 1977 b" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>D'Elia G, Lehmann J, Raotma H</AU>
<TI>Evaluation of a combination of tryptophan and ECT in the treatment of depression II Biochemical analysis</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1977</YR>
<VL>56</VL>
<NO>4</NO>
<PG>319-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>d'Elia G, Lehmann J, Raotma H</AU>
<TI>Evaluation of the combination of tryptophan and ECT in the treatment of depression I Clinical analysis</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1977</YR>
<VL>56</VL>
<NO>4</NO>
<PG>303-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>d'Elia G, Lehmann J, Raotma H</AU>
<TI>Influence of tryptophan on memory functions in depressive patients treated with unilateral ECT</TI>
<SO>Acta Psychiatrica Scandinavica 57[3], 259-68. 1978</SO>
<YR>1978</YR>
<VL>57</VL>
<NO>3</NO>
<PG>259-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunner-1972" NAME="Dunner 1972" YEAR="1972">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dunner DL, Goodwin FK</AU>
<TI>Effect of L-Tryptophan on brain serotonin metabolism in depressed patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<NO>4</NO>
<PG>364-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunner-1975" NAME="Dunner 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dunner D, Fieve R</AU>
<TI>Affective disorder: studies with amine precursors</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1975</YR>
<VL>132</VL>
<NO>2</NO>
<PG>180-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farkas-1976" NAME="Farkas 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farkas T, Dunner DL, Fieve RR</AU>
<TI>L-Tryptophan in depression</TI>
<SO>Biological Psychiatry</SO>
<YR>1976</YR>
<VL>11</VL>
<NO>3</NO>
<PG>295-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glassman-1969" NAME="Glassman 1969" YEAR="1969">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Glassman A, Platman S</AU>
<TI>Potentiation of a monoamine oxidase inhibitor by tryptophan</TI>
<SO>Journal of Psychiatry Research</SO>
<YR>1969</YR>
<VL>7</VL>
<NO>2</NO>
<PG>83-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1980-a" NAME="Harris 1980 a" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harris B</AU>
<TI>Prospective trial of L-Tryptophan in maternity blues</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>233-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrington-1976" NAME="Herrington 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Herrington R, Bruce A, Johnstone E, Lader M</AU>
<TI>Comparative trial of L-Tryptophan and amitriptyline in depressive illness</TI>
<SO>Psychological Medicine</SO>
<YR>1976</YR>
<VL>6</VL>
<NO>4</NO>
<PG>673-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoes-1981" NAME="Hoes 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hoes M, Loeffen T, Vree T</AU>
<TI>Kinetics of L-Tryptophan in depressive patients: A possible correlation between the plasma concentrations of L-Tryptophan and some psychiatric rating scales</TI>
<SO>Psychopharmacology</SO>
<YR>1981</YR>
<VL>75</VL>
<NO>4</NO>
<PG>350-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoes MJ, Sijben N</AU>
<TI>The clinical significance of disordered renal excretion of xanthurenic acid in depressive patients</TI>
<SO>Psychopharmacology</SO>
<YR>1981</YR>
<VL>75</VL>
<NO>4</NO>
<PG>346-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Honore-1982" NAME="Honore 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Honore P, Moller S, Jorgensen A</AU>
<TI>Lithium plus L-Tryptophan compared with amitriptyline in endogenous depression</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>1</NO>
<PG>79-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moller SE, Honore P, Larsen OB</AU>
<TI>Tryptophan and tyrosine ratios to neutral amino acids in endogenous depression. Relation to antidepressant response to amitriptyline and lithium + L-tryptophan</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1983</YR>
<VL>5</VL>
<NO>1</NO>
<PG>67-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobsen-1987-a" NAME="Jacobsen 1987 a" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobsen F, Sack D, Wehr T, Rogers S, Rosenthal N</AU>
<TI>Neuroendocrine response to 5-hydroxytryptophan in seasonal affective disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1987</YR>
<VL>44</VL>
<NO>12</NO>
<PG>1086-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-1975" NAME="Jensen 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jensen K, Fruensgaard K, Ahlfors UG, Pihkanen TA, Tuomikoski S, Ose E et al</AU>
<TI>Tryptophan/imipramine in depression</TI>
<SO>Lancet</SO>
<YR>1975</YR>
<VL>2</VL>
<NO>7941</NO>
<PG>920</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirkegaard-1978" NAME="Kirkegaard 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kirkegaard C, Moller S, Bjorun N</AU>
<TI>Addition of L-Tryptophan to electroconvulsive treatment in endogenous depression</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1978</YR>
<VL>58</VL>
<NO>5</NO>
<PG>457-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kline-1964" NAME="Kline 1964" YEAR="1964">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kline N, Sacks W, Simpson G</AU>
<TI>Further studies on one day treatment of depression with 5-HTP</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1964</YR>
<VL>121</VL>
<PG>379-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kline-1973" NAME="Kline 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kline N, Shah B</AU>
<TI>Comparable therapeutic efficacy of tryptophan and imipramine: average therapeutic ratings versus 'true' equivalence. An important difference.</TI>
<SO>Current Therapeutic Research</SO>
<YR>1973</YR>
<VL>15</VL>
<NO>7</NO>
<PG>484-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levitan-2000" NAME="Levitan 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levitan R, Kennedy S, Shen J, Jindal R, Driver H, Shapiro C</AU>
<TI>Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects</TI>
<SO>Journal of Psychiatry and Neuroscience</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>4</NO>
<PG>337-347</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindberg-1979-a" NAME="Lindberg 1979 a" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindberg D, Ahlfors UG, Dencker SJ, Fruensgaard K, Hansten S, Jensen K et al</AU>
<TI>Symptom reduction in depression after treatment with L-Tryptophan or imipramine. Item analysis of Hamilton rating scale for depression</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1979</YR>
<VL>60</VL>
<NO>3</NO>
<PG>287-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linnoila-1980" NAME="Linnoila 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Linnoila M, Seppala T, Mattila MJ, Vihko R, Pakarinen A, &amp; Skinner T 3rd</AU>
<TI>Clomipramine and doxepin in depressive neurosis</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1980</YR>
<VL>37</VL>
<NO>11</NO>
<PG>1295-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-Ibor-1973" NAME="Lopez Ibor 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayuso Gutierrez JL, Lopez Ibor Alino JL, Montejo Iglesias ML</AU>
<TI>Tryptophan and amitriptyline in the treatment of depression (double blind study)</TI>
<TO>Triptofano y amitriptilina en el tratamiento de la depresion (estudio doble ciego)</TO>
<SO>Actas Luso Espanolas de Neurologia Psiquiatria y Ciencias Afines</SO>
<YR>1973</YR>
<VL>1</VL>
<NO>3</NO>
<PG>471-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lopez Ibor Alino J, Ayuso Gutierrez J, Montejo Iglesias M</AU>
<TI>Tryptophan and amitriptyline in the treatment of depression: A double blind study</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1973</YR>
<VL>8</VL>
<PG>145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucca-1995" NAME="Lucca 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lucca A, Lucini V, Catalano M, Smeraldi E</AU>
<TI>Neural amino acid availability in two major psychiatric disorders</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>4</NO>
<PG>615-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacSweeney-1975" NAME="MacSweeney 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>MacSweeney D</AU>
<TI>Treatment of unipolar depression</TI>
<SO>Lancet</SO>
<YR>1975</YR>
<VL>2</VL>
<NO>7933</NO>
<PG>510-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matussek-1974" NAME="Matussek 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matussek N, Angst J, Benkert O, Gmur M, Pappousek M, Ruther E et al</AU>
<TI>The effect of L-5-Hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro 4-4602) in depressive patients</TI>
<SO>Advances in Biochemical Psychopharmacology</SO>
<YR>1974</YR>
<VL>11</VL>
<NO>0</NO>
<PG>399-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCance_x002d_Katz-1992" NAME="McCance-Katz 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCance-Katz L, Price L, Charney D, Henninger G</AU>
<TI>Serotonergic function during lithium augmentation of refractory depression</TI>
<SO>Psychopharmacology</SO>
<YR>1992</YR>
<VL>108</VL>
<NO>1-2</NO>
<PG>93-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGrath-1990" NAME="McGrath 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McGrath R, Buckwald B, Resnick E</AU>
<TI>The effect of L-Tryptophan on seasonal affective disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51</VL>
<NO>4</NO>
<PG>162-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-1984" NAME="Meltzer 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer H, Perline R, Tricou B, Loewe M, Robertson A</AU>
<TI>Effect of 5-Hydroxytryptophan on serum cortisol levels in major affective disorders II Relation to suicide</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>4</NO>
<PG>379-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY, Lowy M, Robertson A, Goodnick P, Perline R</AU>
<TI>Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. III. Effect of antidepressants and lithium carbonate</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>4</NO>
<PG>391-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendels-1975-b" NAME="Mendels 1975 b" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mendels J, Stinnett J, Burns D, Frazer A</AU>
<TI>Amine precursors and depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1975</YR>
<VL>32</VL>
<NO>1</NO>
<PG>22-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendlewicz-1980-b" NAME="Mendlewicz 1980 b" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mendlewicz J, Youdim M</AU>
<TI>Antidepressant potentiation of 5-Hydroxytryptophan by L-Deprenil in affective illness</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1980</YR>
<VL>2</VL>
<NO>2</NO>
<PG>137-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1974" NAME="Murphy 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy D, Baker M, Goodwin F, Miller H, Kotin J, Bunney Jr W</AU>
<TI>L-Tryptophan in affective disorders: Indoleamine changes and differential clinical effects</TI>
<SO>Psychopharmacologia</SO>
<YR>1973</YR>
<VL>34</VL>
<NO>1</NO>
<PG>11-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nolen-1985" NAME="Nolen 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nolen W, van de Putte J, Dijken W,; Kamp J</AU>
<TI>L-5-HTP in depression resistant to reuptake inhibitors. An open comparative study with tranylcypromine</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>147</VL>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolen WA</AU>
<TI>Tranylcypromine in depression resistant to cyclic antidepressions</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>1-2</NO>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nolen-1988-a" NAME="Nolen 1988 a" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ et al</AU>
<TI>Treatment strategy in depression II MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1988</YR>
<VL>78</VL>
<NO>6</NO>
<PG>676-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nolen-1988-b" NAME="Nolen 1988 b" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ et al</AU>
<TI>Treatment strategy in depression II MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1988</YR>
<VL>78</VL>
<NO>6</NO>
<PG>676-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolen WA</AU>
<TI>Tranylcypromine in depression resistant to cyclic antidepressions</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>1-2</NO>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poldinger-1991" NAME="Poldinger 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poldinger W, Calanchini B, Schwarz W</AU>
<TI>A functional-dimensional approach to depression: Serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine</TI>
<SO>Psychopathology</SO>
<YR>1991</YR>
<VL>24</VL>
<NO>2</NO>
<PG>53-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prange-1974-a" NAME="Prange 1974 a" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prange A Jr, Wilson I, Lynn C, Alltop L, Stikeleather R</AU>
<TI>L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1974</YR>
<VL>30</VL>
<NO>1</NO>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-1998" NAME="Price 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Price L, Mallison R, McDougle C, Pelton G, Henninger G</AU>
<TI>The neurobiology of tryptophan depletion in depression: Effects of intravenous tryptophan infusion</TI>
<SO>Biological Psychiatry</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>5</NO>
<PG>339-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quadbeck-1984" NAME="Quadbeck 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Quadbeck H, Lehmann E, Tegeler J</AU>
<TI>Comparison of the antidepressant action of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine</TI>
<SO>Neuropsychobiology</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>2</NO>
<PG>111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rao-1976" NAME="Rao 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rao B, Broadhurst A</AU>
<TI>Tryptophan and depression</TI>
<SO>BMJ</SO>
<YR>1976</YR>
<VL>1</VL>
<PG>460</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raotma-1978" NAME="Raotma 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raotma H</AU>
<TI>Has tryptophan any anticonvulsive effect?</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1978</YR>
<VL>57</VL>
<NO>3</NO>
<PG>253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rousseau-1987" NAME="Rousseau 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rousseau J</AU>
<TI>Effects of a levo-5-hydroxytryptophan-dihydroergocristine combination on depression and neuropsychic performance: a double blind, placebo controlled clinical trial in elderly patients</TI>
<SO>Clinical Therapeutics</SO>
<YR>1987</YR>
<VL>9</VL>
<NO>3</NO>
<PG>267-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russ-1990" NAME="Russ 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russ M, Ackerman S, Banay-Schwartz M, Shindledecker R, Smith G</AU>
<TI>Plasma tryptophan to large neutral amino acid ratios in depressed and normal subjects</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salomon-1994" NAME="Salomon 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Salomon R, Delgado P, Licinio J, Krystal J, Hennenger G, Charney D</AU>
<TI>Effects of sleep deprivation on serotonin function in depression</TI>
<SO>Biological Psychiatry</SO>
<YR>1994</YR>
<VL>36</VL>
<NO>12</NO>
<PG>840-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seppala-1978" NAME="Seppala 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Seppala T, Linnoila N, Matila M</AU>
<TI>Psychomotor skills in depressed outpatients treated with L-tryptophan, doxepin, or chlorimipramine</TI>
<SO>Annals of Clinical Research</SO>
<YR>1978</YR>
<VL>10</VL>
<NO>4</NO>
<PG>214-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-1970" NAME="Shaw 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shaw D</AU>
<TI>L-Tryptophan in depression</TI>
<SO>Lancet</SO>
<YR>1970</YR>
<VL>1</VL>
<NO>7656</NO>
<PG>1111</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-1972" NAME="Shaw 1972" YEAR="1972">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shaw D, Johnson A, Macsweeney D</AU>
<TI>Tricyclic antidepressants and tryptophan in unipolar affective disorder</TI>
<SO>Lancet</SO>
<YR>1972</YR>
<VL>2</VL>
<NO>789</NO>
<PG>1245</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaw DM, Macsweeney DA, Hewland R, Johnson AL</AU>
<TI>Tricyclic antidepressants and tryptophan in unipolar depression</TI>
<SO>Psychological Medicine</SO>
<YR>1975</YR>
<VL>5</VL>
<NO>3</NO>
<PG>276-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1984" NAME="Smith 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith DF, Stromgren E, Petersen HN, Williams DG, Sheldon W, Angst J et al</AU>
<TI>Lack of effect of tryptophan treatment in demented gerontopsychiatric patients: A double-blind, crossover-controlled study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1984</YR>
<VL>70</VL>
<NO>5</NO>
<PG>470-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinberg-1999" NAME="Steinberg 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steinberg S, Annable L, Young S, Liyanage N</AU>
<TI>A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria</TI>
<SO>Biological Psychiatry</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>3</NO>
<PG>313-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walinder-1975" NAME="Walinder 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walinder J, Skott A, Carlsson A, Nagy A, Bjorn-Erik R</AU>
<TI>Potentiation of the antidepressant action of clomipramine by tryptophan</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1384-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walinder J, Skott A, Nagy A, Carlsson A, Roos B</AU>
<TI>Potentiation of antidepressant action of clomipramine by tryptophan</TI>
<SO>Lancet</SO>
<YR>1975</YR>
<VL>1</VL>
<NO>7913</NO>
<PG>984</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Worrall-1979-b" NAME="Worrall 1979 b" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Worrall EP, Moody JP, Peet M, Dick P, Smith A, Chambers C et al</AU>
<TI>Controlled studies of the acute antidepressant effects of lithium</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>135</VL>
<PG>255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zarcone-1977" NAME="Zarcone 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zarcone V Jr, Berger P, Brodie K, Sack R, Barchas J</AU>
<TI>The indoleamine hypothesis of depression: An overview and pilot study</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1977</YR>
<VL>38</VL>
<NO>8</NO>
<PG>646-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-1989" NAME="Zhao 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao H et al</AU>
<TI>A self-body double blind clinical study of L-tryptophan and placebo in treated neurosis</TI>
<SO>Acta Academiae Medicinae Hubei</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>3</NO>
<PG>256-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Beckmann-1983" NAME="Beckmann 1983" TYPE="JOURNAL_ARTICLE">
<AU>Beckmann H, Kaspers S</AU>
<TI>Serotonin precursors as an antidepressant: an overview.</TI>
<TO>Serotonin-Vorstufen als Antidepressiva: eine Ubersicht.</TO>
<SO>Fortschritte Neurologie und Psychiatrie</SO>
<YR>1983</YR>
<VL>51</VL>
<PG>176-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blackburn-1997" NAME="Blackburn 1997" TYPE="JOURNAL_ARTICLE">
<AU>Blackburn W</AU>
<TI>Eosinophilia myalgia syndrome</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>6</NO>
<PG>781-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bourne-1968" NAME="Bourne 1968" TYPE="JOURNAL_ARTICLE">
<AU>Bourne H, Bunney W, Colburn R, Davis J, Shaw D, Coppen A</AU>
<TI>Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hind brains of suicidal patients</TI>
<SO>Lancet</SO>
<YR>1968</YR>
<VL>II</VL>
<NO>7572</NO>
<PG>805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coppen-1963" NAME="Coppen 1963" TYPE="JOURNAL_ARTICLE">
<AU>Coppen A, Shaw D, Farrel J</AU>
<TI>Potentiation of the antidepressive effect of a monoamine oxidase inhibitor by tryptophan</TI>
<SO>Lancet</SO>
<YR>1963</YR>
<VL>I</VL>
<PG>79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Elia-1978" NAME="D'Elia 1978" TYPE="JOURNAL_ARTICLE">
<AU>D'Elia G, Hanson L, Raotma H</AU>
<TI>L-tryptophan and 5-hydroxytryptophan in the treatment of depression, a review</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1978</YR>
<VL>57</VL>
<NO>3</NO>
<PG>239-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edgell-1972" NAME="Edgell 1972" TYPE="JOURNAL_ARTICLE">
<AU>Edgell P</AU>
<TI>Depression - the commonest disease</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1972</YR>
<VL>106</VL>
<NO>2</NO>
<PG>175-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gelenberg-1982" NAME="Gelenberg 1982" TYPE="JOURNAL_ARTICLE">
<AU>Gelenberg A, Gibson C, Wojcik J</AU>
<TI>Neurotransmitter precursors for the treatment of depression</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1982</YR>
<VL>18</VL>
<NO>1</NO>
<PG>7-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horowitz-1996" NAME="Horowitz 1996" TYPE="JOURNAL_ARTICLE">
<AU>Horowitz R, Daniels S</AU>
<TI>Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome</TI>
<SO>Journal of Rheumatology</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>Suppl 1</NO>
<PG>81-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jorm-1997" NAME="Jorm 1997" TYPE="JOURNAL_ARTICLE">
<AU>Jorm A, Korten A, Rodgers B, Pollitt P, Jacomb P, Christensen H et al</AU>
<TI>Belief systems of the general public concerning the appropriate treatments for mental disorders</TI>
<SO>Social Psychiatry &amp; Psychiatric Epidemiology</SO>
<YR>1997</YR>
<VL>32</VL>
<NO>8</NO>
<PG>468-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lader-1981" NAME="Lader 1981" TYPE="BOOK_SECTION">
<AU>Lader M, Herrington R</AU>
<TI>Drug treatment in psychiatry - psychotropic drugs</TI>
<SO>Handbook of Biological Psychiatry</SO>
<YR>1981</YR>
<VL>5</VL>
<ED>Praag H, Lader H, Rafaelsen O, Sachar E</ED>
<PB>Marcel Dekker</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Michelson-1994" NAME="Michelson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Michelson D, Page S, Casey R, Trucksess M, Love L, Milstien S et al</AU>
<TI>An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan</TI>
<SO>Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>12</NO>
<PG>2261-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1978" NAME="Murphy 1978" TYPE="BOOK_SECTION">
<AU>Murphy D, Campbell I, Costa J</AU>
<TI>Current status of the indolamine hypothesis of the affective disorders</TI>
<SO>Psychopharmacology: A generation of progress</SO>
<YR>1978</YR>
<ED>Lipton M, DiMascio A, Killam R</ED>
<PB>Raven Press</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pare-1959" NAME="Pare 1959" TYPE="JOURNAL_ARTICLE">
<AU>Pare C, Sandler M</AU>
<TI>Clinical and biochemical study of a trial of iproniazid in the treatment of depression</TI>
<SO>Journal of neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1959</YR>
<VL>22</VL>
<PG>247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pare-1969" NAME="Pare 1969" TYPE="JOURNAL_ARTICLE">
<AU>Pare C, Yeung D, Price K, Stacey R</AU>
<TI>5-hydroxytryptamine, noradrenaline, and dopamine in brainstem, hypothalamus, and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning</TI>
<SO>Lancet</SO>
<YR>1969</YR>
<VL>II</VL>
<NO>7612</NO>
<PG>133-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Praag-1981" NAME="Praag 1981" TYPE="JOURNAL_ARTICLE">
<AU>Praag H</AU>
<TI>Management of depression with serotonin precursors</TI>
<SO>Biological Psychiatry</SO>
<YR>1981</YR>
<VL>16</VL>
<NO>3</NO>
<PG>291-310</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rousseau-1987" NAME="Rousseau 1987" TYPE="JOURNAL_ARTICLE">
<AU>Rousseau J</AU>
<TI>Effects of a Levo-5-Hydroxytryptophan-Dihydroergocristine combination on depression and neuropsychic performance: A double-blind placebo-controlled clinical trial in elderly patients</TI>
<SO>Clinical Therapeutics</SO>
<YR>1987</YR>
<VL>9</VL>
<NO>3</NO>
<PG>267-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaw-1967" NAME="Shaw 1967" TYPE="JOURNAL_ARTICLE">
<AU>Shaw D, Camps F, Eccleston E</AU>
<TI>5-Hydroxytryptamine in the hind brain of depressive suicides</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1963</YR>
<VL>113</VL>
<PG>1407</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toyo_x0027_oka-1991" NAME="Toyo'oka 1991" TYPE="JOURNAL_ARTICLE">
<AU>Toyo'oka T, Yamazaki T, Tanimoto T, Sato K, Sato M, Toyoda M et al</AU>
<TI>Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography</TI>
<SO>Chemical and Pharmaceutical Bulletin</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>3</NO>
<PG>820-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trindade-1997" NAME="Trindade 1997" TYPE="BOOK">
<AU>Trindade E; Menon D</AU>
<TI>Selective serotonin reuptake inhibitors (SSRIs) for major depression: Part 1 Evaluation of the clinical literature</TI>
<SO>CCOHTA</SO>
<YR>1997</YR>
<PB>Canadian Coordinating Office for Health Technology Assessment (CCOHTA)</PB>
<CY>Ottawa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wurtman-1976" NAME="Wurtman 1976" TYPE="JOURNAL_ARTICLE">
<AU>Wurtman R, Fernstrom J</AU>
<TI>Control of brain neurotransmitter synthesis by precursor availability and nutritional state</TI>
<SO>Biochemical Pharmacology</SO>
<YR>1976</YR>
<VL>25</VL>
<NO>15</NO>
<PG>1691-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wurtman-1981" NAME="Wurtman 1981" TYPE="JOURNAL_ARTICLE">
<AU>Wurtman R, Hefti F, Melamed E</AU>
<TI>Precursor control of neurotransmitter synthesis</TI>
<SO>Pharmacological Reviews</SO>
<YR>1981</YR>
<VL>32</VL>
<NO>4</NO>
<PG>315-35</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Thomson-1982">
<CHAR_METHODS>
<P>Randomized, double blind placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 patients with mild depression of at least 2 weeks duration, aged 18-65 years, and 26 controls. 7 patients dropped out of the treatment group and 13 dropped out of the placebo group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Placebo for 1 week followed by 12 weeks of L-Tryptophan 1 gram tds, placebo group received identical placebo capsules for 13 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Hamilton Depression Rating Scale, Global Rating Scale, and Visual Analogue Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Over 15% dropout rate, 7 withdrawals in active treatment group, 1 due to epigastric pain and 2 due to dizziness</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Van-Praag-1972">
<CHAR_METHODS>
<P>Randomized, double blind placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 severely depressed inpatients for whom ECT therapy was being contemplated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>3 weeks of 5-Hydroxytryptophan given as 200 mg capsules at a dosage increasing to 3 grams daily and to a total of 50 grams per 3 weeks (total duration 3 weeks) followed by 2 weeks of placebo. Identical placebo was given to the control group for a total duration of 5 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Hamilton Depression Rating Scale, Venables Scale and Zung Rating Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Patients also received barbiturates as needed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Alino-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No group treated with 5-hydroxytryptophan alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Angst-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Asheychik-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Alcoholic patients<BR/>No intention to treat analysis performed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ayuso-1971-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo, no group treated with tryptophan alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barker-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo, no group treated with tryptophan alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barr-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had obsessive-compulsive disorder and not depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brewerton-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had bulimia, no clinically useful measurement of change in depressive symptoms made</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carroll-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized, no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chouinard-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cooper-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to extract data for unipolar patients alone, patients had major medical comorbidities</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coppen-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coppen-1976-c">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-D_x0027_Elia-1977-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Republication of previous study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dunner-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dunner-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Farkas-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Crossover study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Glassman-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomisation performed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harris-1980-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had maternity blues and not depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herrington-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoes-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomisation, not double blind, no intention to treat analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Honore-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo, no patients treated with tryptophan alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jacobsen-1987-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had seasonal affective disorder and not depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jensen-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kirkegaard-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kline-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomisation, no intention to treat, no standardised assessment, no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kline-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levitan-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Tryptophan given in combination with fluoxetine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindberg-1979-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Linnoila-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Tryptophan was the placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lopez-Ibor-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lucca-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MacSweeney-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matussek-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open study - no randomisation, no blinding and no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCance_x002d_Katz-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not about primary outcome of our study, not randomized, IV tryptophan as single dose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McGrath-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had seasonal affective disorder and not depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meltzer-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized, no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mendels-1975-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to extract data for unipolar patients alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mendlewicz-1980-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to extract data for unipolar patients alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murphy-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Crossover study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nolen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No blinding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nolen-1988-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nolen-1988-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No Placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poldinger-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prange-1974-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had mania and not depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Price-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Tryptophan depletion was the subject of study, not tryptophan administration to treat depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Quadbeck-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomisation, no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rao-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raotma-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No measurement of depressive symptoms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rousseau-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>No treatment group administered tryptophan alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Russ-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case-control study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salomon-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized, no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seppala-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shaw-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shaw-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Crossover study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steinberg-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had premenstrual dysphoria and not depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walinder-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No treatment group administered tryptophan alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Worrall-1979-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zarcone-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhao-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Crossover study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Thomson-1982">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Van-Praag-1972">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>L-Tryptophan and 5-HTP versus placebo for the treatment of depression</NAME>
<DICH_OUTCOME CHI2="0.9878618113912228" CI_END="13.146516519248097" CI_START="1.2806561857784207" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.1031899422051215" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.118810691465759" LOG_CI_START="0.1074325515551874" LOG_EFFECT_SIZE="0.6131216215104732" METHOD="PETO" NO="1" P_CHI2="0.3202657611711436" P_Q="1.0" P_Z="0.017484674410080666" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="20" WEIGHT="100.0" Z="2.3763541031440187">
<NAME>Numbers of responders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.220626849475474" CI_START="0.8223974004242814" EFFECT_SIZE="3.037731777517483" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="1.050017119813517" LOG_CI_START="-0.08491827113962415" LOG_EFFECT_SIZE="0.4825494243369465" ORDER="705" O_E="2.5" SE="0.6666666666666666" STUDY_ID="STD-Thomson-1982" TOTAL_1="21" TOTAL_2="15" VAR="2.25" WEIGHT="79.41176470588236"/>
<DICH_DATA CI_END="170.31059599185897" CI_START="1.0052470553899908" EFFECT_SIZE="13.084503243246594" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.231241668735591" LOG_CI_START="0.002272809623989908" LOG_EFFECT_SIZE="1.1167572391797904" ORDER="706" O_E="1.5" SE="1.3093073414159544" STUDY_ID="STD-Van-Praag-1972" TOTAL_1="5" TOTAL_2="5" VAR="0.5833333333333333" WEIGHT="20.588235294117645"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Side-effects of L-Tryptophan and 5-HTP versus placebo</NAME>
<DICH_OUTCOME CHI2="3.2768521646751696E-6" CI_END="54.1866994466098" CI_START="1.0138993560512743" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.412142718233483" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.733892698608279" LOG_CI_START="0.005994847225253471" LOG_EFFECT_SIZE="0.8699437729167663" METHOD="PETO" NO="1" P_CHI2="0.9985556639585841" P_Q="1.0" P_Z="0.04843134507593632" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="31" WEIGHT="100.0" Z="1.9735639605396913">
<NAME>Numbers with side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.65715346836453" CI_START="0.7374898269574086" EFFECT_SIZE="7.420167868216786" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8730714271044953" LOG_CI_START="-0.13224396603011587" LOG_EFFECT_SIZE="0.8704137305371896" ORDER="707" O_E="1.4444444444444444" SE="1.1779321883985585" STUDY_ID="STD-Thomson-1982" TOTAL_1="28" TOTAL_2="26" VAR="0.7207081295131609" WEIGHT="74.24560561521386"/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="708" O_E="0.5" SE="2.0" STUDY_ID="STD-Van-Praag-1972" TOTAL_1="5" TOTAL_2="5" VAR="0.25" WEIGHT="25.75439438478613"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Did review contain a Coppen paper?</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>I cannot find the studies reviewed for the Tryptophan review. Do they include a fascinating study in about 1975, by Dr A Coppin, in London, that showed L-tryptophan, combined with vitamins B6 and C, in a proprietary blend called Optimax, to be as good as Imipramine in depression? This study is cited in Dr Anthony Hordern's big 1970s book Tranquillity Denied. It may be hard to find in the literature, although I believe it did appear in the British Journal of Psychiatry.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>I have reviewed the comment from Doctor Peers. The study he refers to is listed in the excluded studies of our review and was considered in the meta-analyses. Actually, there are four studies in the excluded studies of our review with Dr Coppen as an investigator. They did not meet inclusion criteria for the review as they were not placebo controlled.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Dr Robert Peers<BR/>GP and nutrition researcher</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>